Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 13/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20002497 | 0.77 | RORC (0.44) | RORCGPR6CCR5 | |
| SCHEMBL20002921 | 0.76 | RORC (0.44) | RORCGPR6CCR5 | |
| SCHEMBL20002866 | 0.75 | RORC (0.49) | RORCHTR2AHTR2CKCNH2EPHX2 | |
| SCHEMBL20002828 | 0.74 | RORC (0.54) | RORCHTR2AHTR2CKCNH2EPHX2 | |
| SCHEMBL20002880 | 0.73 | RORC (0.46) | RORCGPR6CCR5 | |
| SCHEMBL20002922 | 0.73 | RORC (0.46) | RORCEPHX2GPR6CCR5 | |
| SCHEMBL20002406 | 0.73 | RORC (0.42) | RORCHTR2AHTR2CKCNH2EPHX2 | |
| SCHEMBL20002460 | 0.73 | RORC (0.55) | RORCHTR2AHTR2CKCNH2EPHX2 | |
| SCHEMBL14413535 | 0.72 | EPHX2 (0.47) | RORCHTR2AHTR2CKCNH2EPHX2 | |
| SCHEMBL20002321 | 0.72 | CCR5 (0.46) | RORCEPHX2GPR6CCR5NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |